William Blair Lifts Earnings Estimates for Exact Sciences

Exact Sciences Corporation (NASDAQ:EXAS) – Stock analysts at William Blair upped their Q2 2025 EPS estimates for Exact Sciences in a research report issued to clients and investors on Monday, June 30th. William Blair analyst A. Brackmann now anticipates that the medical research company will earn $0.06 per share for the quarter, up from their previous forecast of ($0.07). The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. William Blair also issued estimates for Exact Sciences’ Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at $0.22 EPS, Q1 2026 earnings at $0.10 EPS, Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.35 EPS and FY2026 earnings at $1.02 EPS.

Other research analysts have also recently issued research reports about the company. Royal Bank Of Canada increased their price objective on Exact Sciences from $52.00 to $54.00 and gave the stock a “sector perform” rating in a research report on Friday, May 2nd. Evercore ISI upped their price target on shares of Exact Sciences from $60.00 to $66.00 and gave the stock an “outperform” rating in a research note on Friday, May 2nd. Mizuho started coverage on shares of Exact Sciences in a research note on Thursday, April 10th. They issued an “outperform” rating and a $60.00 price objective for the company. Robert W. Baird boosted their price objective on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an “outperform” rating in a report on Friday, May 2nd. Finally, Guggenheim restated a “buy” rating and set a $60.00 target price on shares of Exact Sciences in a research report on Friday, April 11th. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.40.

Exact Sciences Stock Down 1.9%

EXAS opened at $52.82 on Wednesday. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.73 and a quick ratio of 2.38. Exact Sciences has a 12 month low of $39.97 and a 12 month high of $72.83. The stock has a market capitalization of $9.96 billion, a P/E ratio of -9.59, a P/E/G ratio of 11.50 and a beta of 0.95. The business has a 50 day simple moving average of $53.58 and a 200-day simple moving average of $51.28.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.16. The company had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative return on equity of 3.75% and a negative net margin of 36.06%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.60) EPS.

Insider Buying and Selling at Exact Sciences

In related news, Director Katherine S. Zanotti sold 3,207 shares of the firm’s stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $53.20, for a total transaction of $170,612.40. Following the sale, the director owned 72,759 shares in the company, valued at approximately $3,870,778.80. This trade represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its holdings in shares of Exact Sciences by 74.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company’s stock worth $323,669,000 after purchasing an additional 2,462,165 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Exact Sciences by 120.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock valued at $135,453,000 after purchasing an additional 1,707,287 shares during the last quarter. Capital World Investors lifted its position in Exact Sciences by 10.7% during the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company’s stock worth $985,439,000 after buying an additional 1,696,321 shares during the period. Mackenzie Financial Corp boosted its stake in Exact Sciences by 107.7% in the 4th quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company’s stock worth $164,037,000 after buying an additional 1,513,873 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Exact Sciences in the 1st quarter worth about $45,334,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.